ActiGraph Enhances Clinical Trial Efficiency Through Acquisition of Biofourmis

ActiGraph Accelerates Clinical Trial Modernization with Biofourmis Acquisition

ActiGraph, recognized as a leader in wearable digital health technology for clinical research, has made a significant move by acquiring Biofourmis Connect. This strategic acquisition aims to integrate Biofourmis' AI-driven digital trial platform into ActiGraph’s offerings, creating a comprehensive solution for clinical trials. The new system will enhance data collection, analysis, and patient management across various therapeutic areas, ultimately elevating the quality and efficiency of clinical research.

The Biofourmis Connect division has been pivotal in providing a digital ecosystem tailored specifically for the life science sector. This merger will establish a cutting-edge, unified platform that covers the complete life cycle of drug development, ensuring that diverse clinical use cases are adequately supported through a device-agnostic framework. ActiGraph’s renowned medical-grade LEAP wearable technology will be incorporated with other medical devices, like ECGs and pulse oximeters, thus broadening the scope for data collection and real-time monitoring.

Jeremy Wyatt, CEO of ActiGraph, expressed enthusiasm about the acquisition, emphasizing the need for end-to-end support in the clinical development process. Wyatt pointed out that merging their technology with Biofourmis Connect would introduce AI-driven analytics, facilitating a scalable and user-friendly experience for both clinical sites and patients alike. This integration is expected to bolster ActiGraph's already strong leadership in capturing real-time health data, particularly relevant in identifying critical assessments such as pain measurement and predicting risks related to Cytokine Release Syndrome (CRS) in oncology trials.

The collaboration with Biofourmis aims to provide comprehensive digital biomarker programs, emphasizing custom solutions that can adapt to the varying needs within biopharma. The initiative will not only enhance the capabilities of ActiGraph but will also ensure a seamless transition for patients as these digital biomarkers enter the mainstream healthcare landscape.

David Koretz, CEO of Biofourmis, highlighted the importance of this acquisition in further advancing their vision of empowering healthcare providers to improve patient outcomes while effectively managing costs. He noted that Biofourmis' established platform is designed to help hospitals and health systems deliver excellent in-home care, and integrating with ActiGraph will enhance this functionality.

ActiGraph's commitment to revolutionizing clinical trials also aligns with its goal of offering the best possible solutions for data collection and analysis. The company has already supported hundreds of clinical trials and academic research studies, accumulating robust expertise that will now be augmented by Biofourmis' innovative solutions. This acquisition sets the stage for further advancements in digital health technology, making strides towards more efficient and patient-centered clinical development processes.

Overall, this transformational acquisition underscores ActiGraph's readiness to lead in the modernization of clinical trials while expanding the capabilities brought on by AI and other digital health technologies. As the healthcare landscape continually evolves, partnerships such as this pave the way for enhanced outcomes in the field of clinical research.

About ActiGraph

ActiGraph is at the forefront of the digital transformation in clinical research, providing extensive digital health technology solutions by seamlessly integrating hardware, software, and algorithms. Their platform is utilized in numerous industry-supported clinical trials, making them a highly regarded partner in ensuring the delivery of accurate medical insights.

About Biofourmis

Biofourmis specializes in remote, at-home care solutions tailored for healthcare providers. Their AI-driven platform effectively covers the entire spectrum of patient needs, from pre- to post-surgical care, enhancing patient outcomes while streamlining costs across the healthcare system.